Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4705957 | 0.87 | CYP1A2 (0.42) | DHFRHSD11B1PTPN1PIK3R1PIK3CA | |
| SCHEMBL4707590 | 0.87 | PTPN1 (0.48) | HSD11B1PTPN1PIK3R1PIK3CA | |
| SCHEMBL4688098 | 0.85 | DHFR (0.49) | DHFRSLC2A1ADORA2A | |
| SCHEMBL4707409 | 0.85 | PTPN1 (0.51) | HSD11B1PTPN1 | |
| SCHEMBL4707308 | 0.85 | HSD11B1 (0.39) | HSD11B1PTPN1PIK3R1PIK3CABACE1 | |
| SCHEMBL4706070 | 0.85 | NPY5R (0.42) | HSD11B1PTPN1 | |
| SCHEMBL4688933 | 0.84 | SLC2A1 (0.40) | SLC2A1PTPN1 | |
| SCHEMBL4705958 | 0.84 | NPY5R (0.43) | HSD11B1PTPN1 | |
| SCHEMBL4687414 | 0.84 | DHFR (0.55) | DHFRSLC2A1ADORA2A | |
| SCHEMBL4707892 | 0.83 | HSD11B1 (0.37) | HSD11B1PTPN1PIK3R1PIK3CABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | claimed |
| EP-1633754-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-06-11 | — | — | EP | disclosed |
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7226915-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | disclosed |
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PPP5C, PTP4A2 | DHFR 289/4885HSD11B1 4521/4885SLC2A1 271/4885 |
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PTPRO, PTPN18 | DHFR 531/4885HSD11B1 4478/4885SLC2A1 293/4885 |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, DUSP15, PPP5C | DHFR 339/4885HSD11B1 4556/4885SLC2A1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.